PCT

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12Q 1/68, C07H 15/12, 17/00 **A1**	(11) International Publication Number: **WO 95/18868** (43) International Publication Date: 13 July 1995 (13.07.95)

(21) International Application Number: PCT/US95/00266

(22) International Filing Date: 9 January 1995 (09.01.95)

(30) Priority Data:
     08/179,972   11 January 1994 (11.01.94)   US

(60) Parent Application or Grant
   (63) Related by Continuation
     US   08/179,972 (CIP)
     Filed on   11 January 1994 (11.01.94)

(71) Applicant *(for all designated States except US)*: ISIS PHAR-MACEUTICALS, INC. [US/US]; 2280 Faraday Avenue, Carlsbad, CA 92008 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: COOK, Phillip, Dan [US/US]; 641 Avilar Court, San Marcos, CA 92069 (US). ECKER, David, J. [US/US]; 1041 Saxony Road, Leucadia, CA 92024 (US). ACEVEDO, Oscar, L. [US/US]; 12117 Brickellia, San Diego, CA 92129 (US). DAVIS, Peter, W. [US/US]; 2202 Highland Drive, Carlsbad, CA 92008 (US).

(74) Agents: CALDWELL, John, W. et al.; Woodcock Washburn Kurtz Mackiewicz & Norris, 46th floor, One Liberty Place, Philadelphia, PA 19103 (US).

(81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
    With international search report.

(54) Title: RANDOM OLIGONUCLEOTIDE LIBRARIES AND METHODS OF MAKING THE SAME

(57) Abstract

The present invention provides methods of analyzing and evaluating phosphorus bearing monomeric units as to their suitability for use in preparing random oligomer libraries. The invention further provides methods for preparing such random oligomer libraries from the selected monomers.

TITLE: RANDOM OLIGONUCLEOTIDE LIBRARIES AND METHODS OF
         MAKING THE SAME

CROSS REFERENCE TO RELATED APPLICATION

         This is a continuation-in-part of U.S. Serial No.
5 08/179,972 filed January 11, 1994, the contents of which are
incorporated by reference herein in their entirety.

FIELD OF THE INVENTION

         The invention is related to the field of combinatorial
libraries and methods of making the same.

10 BACKGROUND OF THE INVENTION

         There is an increasing need to find new molecules that
can effectively modulate a wide range of biological processes.
Rational drug design methodologies which have been used his-
torical to design new drugs and other useful compositions, have
15 been limited by the fact that the new drugs are generally
derived from a known starting point. Recently, new technolo-
gies have focused on non-rational drug design. These methodol-
ogies generally rely upon the use of combinatorial libraries of
randomly created polymers. Some work has been done to optimize
20 the "randomness" of peptide libraries. Rutter and Santi, U.S.
patent 5,010,175, focuses upon identifying the binding rate
constants of amino acid units and modifying incorporation of
each amino acid depending upon the rate constant for a given
amino acid. Lam, et al., PCT/US91/04666 filed July 1, 1991,
25 teach coupling amino acid units to a solid support, mixing the
solid supports, and aliquoting the solid supports into equal
portions. Thereafter the coupling, aliquoting, and mixing are

- 2 -

repeated. Similarly, Owens, et al., 1991, *Biochem. Biophys. Res. Comm.*, **181**, 402-408, teach several coupling reactions each with different amino acids conducted simultaneously and then combined to generate a near equimolar mixture before coupling
5 additional residues. Houghten et al., PCT/US91/08694 filed November 20, 1991, teach a process for the synthesis of a complex mixture pool of solid support-coupled monomeric repeating units, such as amino acids, by reacting the monomeric units with solid supports and mixing the solid supports linked
10 to the monomeric units to form a reaction product pool. Thereafter the reaction pool is separated into a number of aliquots of equal weight and the process is repeated to produce peptides of a desired length.

As compared to amino acids, nucleotide monomers and
15 chemical species related thereto represent a very different class of chemicals having very different properties. These difference are of such extent so as to require very dissimilar chemistries to prepare polymeric species from the monomers. Additionally they present other problems and differences such
20 as purification that must be overcome in the preparation of random libraries. Until now, little work has been done to optimize the preparation and use of nucleotide based combina-torial libraries. Huse, et al., PCT/US91/05939 filed August 20, 1991, teach a method of synthesizing oligonucleotides
25 having random tuplets (i.e. doublets, triplets, or quartets) using individual monomers whereby monomers are sequentially coupled in separate reaction vessels on separate supports. Thereafter the supports are mixed, and the mixture is aliquoted. The tuplets are designed so as to provide the
30 entire genetic code, excepting those degenerate codons.

Methods of reducing bias by equalizing binding of each unit in an oligonucleotide pool are greatly desired. These and other objects are provided by the present invention.

SUMMARY OF THE INVENTION
35 In some embodiments of the present invention there are provided methods of preparing a random phosphate linked oligo-

- 3 -

mer library comprising selecting a group of phosphorous bearing monomers, testing the group of monomers for chemical suitability and selecting from the group of phosphorous bearing monomers those monomers that are chemically suitable. The
5 selected monomers are reacted with a solid support and the relative coupling efficiency of each phosphorous bearing monomer unit to the solid support is determined. Based upon the determined coupling efficiency, a mixture of the selected phosphorous bearing monomer units is prepared and the mixture
10 is reacted to a solid support or growing oligomer chain. The cycle may be repeated to prepare a random oligomer library in which the oligomers are of a desired length.

In other embodiments of the present invention methods of preparing a random phosphate linked oligomer library are
15 provided comprising selecting a group of phosphorous bearing monomers to be tested, testing the phosphorous bearing monomers for chemical suitability, selecting from the group of phosphorous bearing monomers those monomers that are chemically suitable and individually reacting to completion via phosphate
20 couplings each of the chemically compatible phosphorous bearing monomers with a solid support or growing oligomer chain. Thereafter, all of the solid supports are combined to form a mixture and the mixture is again divided into portions. The cycle is repeated until a random oligomer library comprising oligomers
25 of a desired length is prepared.

The invention further includes oligomeric compounds prepared using the methods of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides methods of preparing
30 random oligomer libraries. In accordance with methods of the present invention, a group of phosphorous bearing monomers are selected. The term "phosphorous bearing monomer" as used herein refers to nucleotide monomers comprising a nucleoside and a phosphate moiety that can form a phosphate backbone
35 linkage upon coupling one monomer to the next. Nat ally occurring nucleotides such as adenosine, thymidine, cytidine,

- 4 -

guanosine and uridine are well known phosphorous bearing monomers. In some preferred embodiments of the present invention nucleotide analogs may also be used. For example purines and pyrimidines other than those normally found in

5   nature may be employed. Suitable purine, pyrimidine and other heterocyclic bases include those disclosed in: United States patent 3,687,808 to Merigan et al., Englisch et al., *Angewandte Chemie*, International Edition, **1991**, *30*, 613-722 (see especially pages 622 and 623, and the *Concise Encyclopedia of*

10 *Polymer Science and Engineering*, J.I. Kroschwitz Ed., John Wiley & Sons, **1990**, pages 858-859. Monomers having modifications on the furanosyl portion of the nucleotide subunits may also be used as long as the essential tenets of this invention are adhered to. Examples of such modifications are 2'-O-alkyl-

15 and 2'-halogen-substituted nucleotides. Some specific examples of modifications at the 2' position of sugar moieties which are useful in the present invention are OH, SH, SCH_3, F, OCN, $O(CH_2)_nNH_2$, $O(CH_2)_nCH_3$ where n is from 1 to about 10; C_1 to C_{10} lower alkyl, substituted lower alkyl, alkaryl or aralkyl; Cl,

20 Br, CN, CF_3, OCF_3, O-, S-, or N-alkyl; O-, S-, or N-alkenyl; $SOCH_3$, SO_2CH_3; ONO_2; NO_2; N_3; NH_2; heterocycloalkyl; heterocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a conjugate; a reporter group; an intercalator; a group for improving the pharmacokinetic

25 properties of an oligonucleotide; or a group for improving the pharmacodynamic properties of an oligonucleotide and other substituents having similar properties. Sugar mimetics such as cyclobutyl and glyceryl may also be used in place of the pentofuranosyl group.

30   This group of monomers is tested for chemical suitability for use in combinatorial chemistry and a sub-group of monomers which are chemically suitable are selected. Chemical suitability can be measured by the following factors. The monomers should be incorporated to roughly the same degree

35 and with sufficient efficiency to give a majority of full-length oligomer product; the product of a coupling reaction is predominantly the desired product; and the monomer should be

- 5 -

stable to the selected synthesis and deprotection conditions of
the system. In addition, it may be preferable that the monomer
have few or no special handling requirements, such as treatment
with a special reagent, extended deprotection time, excessively
5 high reaction time, or excessive reagent use. For example,
monomers which require lengthy deprotection may not be suitable
for use with other monomers which cannot tolerate lengthy
deprotection. Incompatibility with an organic base which is
necessary for deprotection of one or more additional monomers
10 is also an indication that such monomer is not suitable for a
particular use. For example, in one embodiment of the present
invention, suitable monomers should react at from about 0.1 to
about 0.2 M concentration and be amenable to deprotection in
concentrated ammonia at 55°C overnight. Monomers which are not
15 suitable will result in products that include undesirable
impurities due to insufficient reactivity or excessive sensi-
tivity to concentrated ammonia treatment.

        Once a sub-group of monomers which are chemically
suitable have been selected, oligomer libraries may be
20 prepared. In accordance with the present invention, two
methods are useful. In one preferred embodiment, mixtures of
chemically suitable monomers are prepared. Preferably,
phosphoramidites are dissolved in anhydrous acetonitrile to
give a solution having a given ratio of amidite concentrations.
25 By creating a mixture of monomers in solution, the mixture can
be treated as if it contains only a single monomer on an
automated synthesizer, thereby bypassing user interaction
during coupling. The mixture of known chemically compatible
monomers is reacted to a solid support, or further along, may
30 be reacted to a growing chain of monomer units.

        The terminology via "phosphate coupling" as used
herein is understood to including effecting a coupling using
phosphate P^V coupling (true phosphate coupling) or a coupling
using a phosphate precursor such as a P^{III} coupling (a phosphite
35 coupling). Such coupling thus includes the use of amidite
(phosphoramidite), triester, H-phosphonate, halide and solution
phase couplings. A preferred coupling method is via the so

- 6 -

called "phosphoramidite coupling" (a phosphite coupling). In using this coupling method, after the phosphite coupling is complete the resulting phosphite is oxidized to a phosphate. Oxidation can be effected with oxygen to give phosphates or
5   with sulfur to give phosphorothioates.

In each of the methods of the invention, the solid supports which are useful are well known in the art. For example, controlled pore glass (CPG) solid support beads are commonly used. Other useful solid supports that may be used in
10 methods of the present invention include polystyrene resins, derivatized polystyrene resins, graft polymers of polyoxyethylene and polyvinyl alcohol, polyhydroxy-styrene or chloromethylated polystyrene crosslinked with ethylene glycol, oligoethylene glycol, polyacrylate polymer, and polymethacrylate
15 polymer functionalized with hydroxy groups. Polyacrylmorpholide support resins may also be used in some methods of the present invention. Inorganic supports may also be used including silicon based compounds. Of course other solid supports known to those skilled in the art may also be employed
20 in methods of the present invention. Supports useful in methods of the present invention are reactive to monomers useful in methods of the present invention via "standard reactive sites" by which coupling is accomplished. By way of example, a standard reactive site of CPG is a long-chain with
25 a terminal alkyl amine functionality coupled with a deoxynucleoside succinate. The rest of the CPG support being ideally and preferably innate.

In those embodiments of the invention wherein it is desirable not to introduce bias in the oligomer libraries of
30 the invention that are a result of having less than all of the possible combinations of nucleotide sequences, preferably, the number of reactive sites on a particular support will be selected to be greater than the number of sequences to be made by orders of magnitude (at least two orders of magnitude) in
35 order to ensure that all possible sequences are represented adequately. Coupling may be achieved using commercially available automated synthesizers such as ABI 394 automated

- 7 -

synthesizer (ABI, Foster City, CA) using standard DNA synthesis reagents.

Since a diversity of nucleotides may be used in preparing oligomer libraries, accounting of the coupling
5 efficiencies of the individual nucleotides may be practiced to eliminate any bias that may be introduced in the oligomer libraries. To mitigate for such bias, the relative incorporation rates of monomers are determined by coupling monomers to supports treated with a nucleotide of interest that
10 is chosen as a standard. The product is analyzed, for instance, by the methods of reverse phase HPLC or capillary gel electrophoresis. For example, peaks in the HPLC chromatograph corresponding to different dinucleotide phosphates are identified and converted to relative molar amounts using the
15 known extinction coefficients at 260nm (ϵ_{260}) or other selected wave length. In practicing certain embodiments of the invention, for the incorporation of a nucleotide analog having modifications that do not change the base ring and do not have any inherent absorbance at 260nm, the nucleotide analogs are
20 assumed to have the same ϵ_{260} as the parent DNA or RNA nucleoside. In practicing other embodiments of the invention, an extinction coefficient, as for example that at 260nm, will be determined experimentally using standard spectrophotometric techniques. In practicing further embodiments, the extinction
25 coefficient can be determined by the following method.

It has been determined that coupling efficiency, estimation of extinction coefficient and evaluation of coupling product quality for any phosphate-bearing monomeric unit can be effected by using standard phosphoramidite coupling chemistry
30 and "standards" such as dT-CPG DNA synthesis support. This includes the commercially available DNA or RNA amidites, as well as like compounds that are useful in oligomer synthesis. Using dT as a symbol for thymidine, dC as a symbol for deoxy cytidine and other abbreviations as note in the text below, in
35 practicing my methods, for example, the standard, deoxy- thymidine derivatized controlled-pore glass (dT-CPG) is used as a solid phase synthesis medium, and unreactive 5'-O-acetyl-

- 8 -

deoxycytidine-derivatized controlled-pore glass (5'-O-Ac-dC-CPG) is used as an "internal reference standard". These could be substituted with any pair of entities, provided that both are compatible with the desired chemistry, both are strong

5   chromophores of known or measurable extinction coefficient at a useful wavelength, and one is reactive while the other is inert to the coupling conditions. The method can be expanded to include other coupling methods and other solid supports that can be analyzed by equivalent means different that those used

10 for illustrative purposes in the examples below. Other examples would include phosphate triester coupling and hydrogen phosphonate coupling.

        Thus, in accordance with methods of the present invention, reactive dT-CPG (a standard) is mixed with a lesser

15 molar equivalent of unreactive 5'-Ac-dC-CPG (internal reference standard). The unreactive 5'-Ac-dC-CPG internal standard allows for accurate determination of unreacted thymidine, i.e. dT, present before and after a coupling reaction.

        The peak area of dT in a HPLC chromatogram can be

20 identified as A_T and the peak area of deoxycytidine in the chromatogram can be identified as A_C. The initial ratio of peak areas for dT and dC is $(A_T/A_C)_0$. Relative moles of dC can be identified as C, and relative moles of dT can be identified as T. These are calculated from peak areas, A_C and A_T,

25 respectively, using known extinction coefficients: $C = A_C/\epsilon_C$ and $T = A_T/\epsilon_T$. Thus the relative peak area or molar amount of dT initially present can be calculated from A_C:

$$A_{T0} = (A_C)[(A_T/A_C)_0]$$
$$T_0 = (C)[(T/C)_0]$$

30 also,

$$(C)(T/C) = (A_C/\epsilon_C)[(A_T/\epsilon_T)/(A_C/\epsilon_C)]$$
$$= (A_C/\epsilon_C)(A_T/A_C))(\epsilon_C/\epsilon_T)$$

    thus,

$$(C)[(T/C)_0] = (A_C/\epsilon_C))[(A_T/A_C)_0](\epsilon_C, \epsilon_T)$$

35

$$= (A_C/\epsilon_T)[(A_T/A_C)_0]$$

- 9 -

An amidite monomer of interest, identified as X, is reacted
with an aliquot of the CPG mixture. Reacted CPG is cleaved and
deprotected with ammonia, then analyzed by HPLC to determine
the area under the peak for dC, i.e. A_C; area under the peak
5 for unreacted dT, i.e. A_{Tur}; and area under the peak for X-T
dimer, i.e. A_{XT}. These values are used to calculate coupling
efficiency, $C.E.$; and X-T dimer extinction coefficient, ϵ_{XT}.

The coupling efficiency, $C.E.$, is defined by the ratio
of reacted dT, i.e. T_r, to total dT, i.e. T_0. Thus $C.E.$ =
10 T_r/T_0. Coupling efficiency can be determined from the relative
moles of unreacted dT present before, i.e. T_0, and after, i.e.
T_{ur}, coupling with X; all three are related by the equation

$$T_0 = T_r + T_{ur}.$$

Since $C.E.$ is a unitless value, HPLC peak areas can
15 be used instead of relative molar quantities to perform the
calculation:

$$
\begin{aligned}
C.E. &= (T_r/T_0) \\
&= (T_0/T_0) - (T_{ur}/T_0) \\
&= 1 - (T_{ur}/T_0) \\
20 \quad &= 1 - (A_{Tur}/\epsilon_T)/(A_{T0}/\epsilon_T) \\
&= 1 - (A_{Tur}/A_{T0}) \\
&= 1 - (A_{Tur})/[(A_C)[(A_T/A_C)_0]]
\end{aligned}
$$

(which are all measurable quantities)

The extinction coefficient ϵ for X, i.e. ϵ_{XT}, in the
25 given HPLC solvent system is determined from the $C.E.$ for X and
the relative areas of the HPLC peaks. The amount of X-T is
equal to the amount of T that has reacted. ϵ for dimer X-T is
defined as the peak area A_{XT} divided by the moles of X-T dimer
present XT, and is calculated as follows:

$$
\begin{aligned}
30 \quad XT &= T_r \\
&= (C.E.)(T_0)
\end{aligned}
$$

- 10 -

$$\epsilon_{XT} = (A_{XT}/XT)$$
$$= (A_{XT})/(C.E.)(T_0)$$
$$= (A_{XT})/(C.E.)(C)[(T/C)_0]$$
$$= (A_{XT})/(C.E.)(A_C/\epsilon_T)[(A_T/A_C)_0]$$
(which again are all measurable quantities)

Finally, the quality of the coupling-product X-T can be evaluated from the appearance of the HPLC chromatogram. Other significant peaks (those summing >10% of product-peak area) can also be addressed. Often they are the desired X-T dimer that retains protective groups. Disappearance of these peaks with extended ammonia treatment will confirm that the monomer requires extended ammonia deprotection beyond the standard time. In other cases the extra peaks can be identified as undesirable side-products and in some cases they cannot be identified. Generally, coupling efficiency of less than about 90%, a required ammonia deprotection time of greater than a few days, or the occurrence of side-products amounting to greater that 10% (by UV absorbance) can be selected as initial guidelines to judge the possibility of excluding an amidite from consideration for use in a particular set of amidites used in generating random oligomeric compounds.

Given the relative incorporation rate, a phosphorous bearing monomer mixture can be adjusted to improve the incorporation rate in order to move towards a desired relative concentration. One preferred relative concentration is an equimolar concentration. In other preferred embodiments of the present invention one or more monomers may be preferentially incorporated by adjusting the ratio of monomers in the mixture in accordance with their relative incorporation rates. Such mixtures that take into account relative incorporation rates are referred to herein as "adjusted" mixtures. For the purposes of this specification, it is assumed that the incorporation is linear with respect to rate constant and concentration. Thus, the relative incorporation rate of monomers that react more slowly can be improved by increasing the relative concentration of the monomer in an adjusted mixture.

- 11 -

Accordingly, the relative volumes of each monomer in the adjusted mixture are the inverse proportion of the relative concentration.

Once the relative incorporation is determined, the
5   amidite mixture is then tailored to improve the relative incorporation rate and make it closer to equimolar. In doing this, as a first approximation, it is assumed that the incorporation is linear with respect to rate constant and concentration, so that the relative incorporation residues that react
10   more slowly can be improved by increasing the relative concentration in a new mixture. The relative volumes of each amidite in the next mix are the inverse proportion of the relative concentration.

In practicing the invention, in some instances only
15   a single optimization cycle need be practiced. In other instances, e.g. with nucleotides have widely divergent initial relative incorporation rates, adjustment to normalize the relative incorporation may be performed more than once in order to optimize normalization within desired limits.
20   In some embodiments of the invention where equimolar incorporation is desired, acceptable limits for unequal incorporation may generally be +/- 10%. In such cases, at no time will the difference between the most and least incorporated residue be more than 20%. For example, a normalized ratio of
25   1.1/1.0/1.0/0.9 is acceptable. However, a normalized ratio of 1.15/1.0/0.95/0.9 may not acceptable in some cases. In this last instance a further adjustment iteration may be effected to bring the rates of incorporation within the set limit.

Of course, where equimolar incorporation is not
30   desired, and instead a fixed, rather than random, position is sought, monomer mixtures should be replaced with a "fixed" monomer. Fixed, as used herein is meant to refer to monomers within an oligomer which are known, set or otherwise predetermined. Accordingly, in the oligonucleotide NNNNGNNN
35   the fifth position is a fixed position which has been predetermined to be a guanosine while the remaining positions may be, randomly, any of the monomers making up the monomer mixture,

- 12 -

the resultant library being all combinations of selected monomers with the proviso that guanosine is the fifth residue.

As used herein, a random oligomer is an oligomer having at least one random position. A fixed position may be incorporated into such random oligomers in accordance with methods of the present invention, by use of the appropriate monomer for incorporating the fixed position within the oligomer during a coupling step. If more than one fixed position is desired, each fixed position is introduced step-wise by use of the appropriate monomer during a coupling step. If more than one fixed position is desirable, such fixed positions can be adjacent to one another in the oligomer sequence or they can be separated in the oligomer sequence by random positions. Whether fixed or random, each position in an oligomer of desired length is added via an iteration of the coupling steps. These steps are repeated until an oligomer library comprising oligomers of a desired length are prepared.

Random phosphate linked oligomer libraries can also be prepared by individually reacting, to completion, each of a selected group of chemically suitable phosphorous bearing monomers with a solid support or growing nucleotide chain using phosphate coupling. Monomers which are coupled one at a time in a non-competitive nature are assumed to couple to completion. Therefore the factors involved in creating equal incorporation are (i) sufficient inherent coupling efficiency for all monomers used and (ii) equal amounts of solid support (reactive sites) for each of the individual coupling reactions. Completeness of a reaction can be monitored for example, by standard DMT-cation assay. Alternately, a post-synthesis analysis can be used to determine how well monomers were incorporated during the synthesis.

Random oligomer pools may be prepared in accordance with this embodiment of the invention by preparing a number of individual aliquots of solid support equal to the number of individual types of monomers which are to be incorporated into the random oligomer library. Thereafter, each of the aliquots is reacted with a different monomer until the reaction goes to

- 13 -

completion. The aliquots are thoroughly mixed and apportioned into a number of aliquots equal to the number of unique monomers to be incorporated during this next step. The apportionment and coupling steps may be performed until an
5 oligomer library comprising oligomers of desired length is prepared.

In a preferred embodiment of the invention that is a variation of the immediately proceeding procedure, one or more fixed positions can be introduced into the oligomer library by
10 refraining from dividing the solid support during one or more of the iterations of the procedure. During the iteration of the proce ure wherein the fixed position is introduced, the totality of the solid support is reacted with the monomer that is desired at the fixed position. This can be repeated if more
15 than one consecutive fixed position is desired. If the fixed position (or positions) are desired at the end of the oligomer, synthesis is halted after the iteration that introduces the fixed position (or positions). However, if additional random positions are desired after the fixed position (or positions),
20 after introduction of the fixed position (or positions) during the next iteration of the procedure, once again the solid support is divided into aliquot and each aliquot reacted with a different monomer.

In a further preferred embodiment of the invention,
25 one or more "fixed positions" may also be incorporated into a randomized oligomer by reacting individual monomers to aliquots of the support, but refraining from mixing the aliquots. Instead, the aliquots are kept separate and each sub-set, or pool, is further divided into the proper number of portions
30 corresponding to the number of monomers to be reacted. Each portion of support is then reacted with a different monomer, followed by mixing and reapportionment of the support within each pool. Repeating this cycle for each of the different sub-sets of supports results in randomization in positions
35 following the fixed position in the sequence. By keeping the pools separate, one obtains separate pools which are unique for one or more monomers at one or more the fixed positions.

- 14 -

In a further preferred embodiment, that can be considered as a variation of the above embodiments, one of the positions introduced is a "null" position - that is it is an "empty" or "nothing" position. This introduces the ability of

5 the random library to address "length-space" as well as "sequence-space." In practicing this embodiment, in one or more iteration of the process, the solid support is divided into a number of aliquots that is one greater than the number of monomer that are to be reacted. One of the aliquots of the

10 solid support is set aside and is not reacted with monomer during a selected iteration of the process. This aliquot is thereafter returned to the pool of aliquots when the set of aliquots of the solid support are recombined. The resulting oligomer pools contain sequences that vary both in sequence and

15 length. The variation in length can be controlled by the number of positions , i.e. times, in which the null position is introduced, from zero positions to give all full-length oligomers, to all positions to give oligomers of length 1 to full-length.

20   In an even further preferred embodiment, that can be also considered as a variation of the above "fixed positions" embodiments, the "fixed" position that is introduced is a "negative fixed position" with respect to one of the monomer - that is the position is selected to not contain a particular

25 monomer. This introduces the ability of the random library to address the absence of a particular monomer at a given position in the resulting oligomer. In practicing this embodiment, in one or more iteration of the process, the solid support is divided in to a number of aliquots that is one less than the

30 number of monomers that are to be reacted. The monomer that is to be absent from the known position is not reacted with one of the aliquots of the solid support while the remaining variable· monomers are. After the iteration that excludes the selected monomer is competed, the aliquots of the set of aliquots of the

35 solid support are recombined and further iterations (or termination) of the oligomer is effected.

Random oligomer libraries are useful as is described,

- 15 -

for example, in published PCT application WO/93/04204. Further
random oligomers libraries are useful as is described in United
States patent applications with Serial No. 080,134, filed
January 11, 1994, Serial No. 179,970, filed Januray 11, 1994,
5 and Serial No. 357,396, filed December 16, 1994, commonly
assigned with this application. The entire contents of these
United States patent applications are herein incorporated by
reference.

Example 1
10   **Determination of Coupling Efficiency and ϵ_{260} of Novel
          Residues**
          A. Preparation of Solid Support Mixture
          5'-O-Ac-dC-support + dT-support was made by first
preparing the dC support that was rendered unreactive by
15 removing the 5'-terminal dimetḥ xytrityl group (i.e. a DMT
group) and "capping" the 5'-hydroxyl with an acetyl group in
accordance with the following procedure. 1 gram of dC-support
(48 μmole dC per gram support, catalog #dC200502, CPG Inc.,
Fairfield, N.J.) was treated with several aliquots of standard
20 deblock solution, 3% trichloroacetic acid in dichloromethane
(approximately 50-70 ml total). This was repeated over several
minutes until no more orange color appeared. The support was
rinsed well with dichloromethane, ethanol, and diethyl ether
and dried under vacuum. The support was then treated with 5 ml
25 each of acetic anhydride and N-methyl imidazole capping
solutions (ABI Cap A reagent solution, acetic anhydride in THF,
catalog #400234, and ABI Cap B reagent solution, N-methyl
imidazole in THF, catalog #400777, both from Applied
biosystems, Foster City, CA). The slurry was shaken in a
30 sealed vial for 20 minutes, filtered, and the support rinsed
with acetonitrile, ethanol, and ether. The support was air-
dried then vacuum dried.
          0.25 g of 5'-O-Ac-dC-CPG was mixed with 1 g of dT-CPG
(40 μmole/gram support, dT CPG support catalog # dT200504, CPG
35 Inc., Fairfield, NJ) to give a dC to dT molar ratio of approxi-
mately 1:4. Two aliquots of the mixture were treated with de-

- 16 -

block solution on the synthesizer to remove the DMT groups, then treated with concentrated ammonia in a sealed vial at 55 °C for 30 minutes to cleave nucleosides from the support and remove exocyclic amine protecting groups. The supernatant was cooled, dried, reconstituted in 0.1 M ammonium acetate, pH 7, and analyzed on a reversed-phase HPLC column (Water Delta Pak C18 300Å, catalog # 035571, Millipore Corp., Milford, Mass.) using a gradient of 1% to 16% acetonitrile in 0.1 M ammonium acetate, pH 7, over 22.5 minutes. The HPLC system is a Waters 991 detector, 625 LC pump, and 715 WISP autoinjector (Millipore, Corp.). Calculations were performed using data collected at a wavelength of 260 nm.

B.   Determination of Coupling Efficiency and Dimer Extinction Coefficient

Synthesis of dimers was performed with an ABI 394 DNA synthesizer (Applied Biosystems, Foster City, CA) using standard DNA synthesis reagents and synthesis protocols, with the exception of an extended (5 minute) coupling time added to the synthesis cycle. 1 μmole of synthesis support from Example 1A was used. Oligomers were cleaved from solid support by treatment with concentrated ammonia for 2 hours at 20 °C. The supernatant was removed from the support and heated in a sealed vial at 55 °C for two hours. This solution was cooled, and most of the ammonia removed by evaporation. Oligomers were analyzed directly on reversed-phase HPLC column (Waters Nova-Pak Phenyl, cat. # 10656, Millipore, Corp.) using a gradient of 1% to 46% acetonitrile in 0.1 M ammonium acetate, pH 7, over 30 minutes and the HPLC system described previously.

Coupling efficiency of 2'-O-pentyladenosine phosphor-amidite and extinction coefficient for the resulting dimer were calculated from peak-areas as described previously:

$$C.E. = 1 - \{A_{Tur} / [A_C(A_T/A_C)_0]\}$$
$$= 1 - \{2.87 / (7.03)(5.57)\}$$
$$= 0.927 \ (92.7\%)$$

- 17 -

$$\epsilon_{XT} = A_{XT} / (C.E.)(A_C/\epsilon_T)[A_T/A_C)_0]$$
$$= 86.77 / (.927)(7.03/8.7)(5.57)$$
$$= 20.8 \ M^{-1}cm^{-1}(10^3)$$

The coupling efficiency of 92.7% exceeds the desired 90% lower
5 limit described previously.   The calculated extinction coef-
ficient of 20.8 compares favorably to the published value of a
DNA dA-dT of 22.84.

Example 2

An equimolar mixture of four DNA amidites (mG, 2'-O-
10 methyl guanosine; mA, 2'-O-methyl adenosine; biA, 2'-O-
butylimidazolyl adenosine; and nC, 2'-O-nonyl cytidine) was
coupled to dT-CPG mix as described in Example 1.   The results
of these couplings are as shown in Table I.   The initial
ʋ⁻ qual incorporation favors biA and disfavors nC as is shown
15 i the third column.   To mitigate this, the relative amount of
nC amidite is increased by the inverse of the relative
incorporation as is shown in the fourth column and is
normalized for the particular volume, i.e. 400 μl, in the fifth
column.   The new adjusted mixture is shown in the sixth column
20 and for the next coupling the relative incorporations are
nearly equal as is seen in the seventh column.

- 18 -

Table I

nucleotide	amount 0.1M (ul)	relative incorporation for 1:1 mixture	(relative incorporation)$^{-1}$	*	new amount (0.1M (µL)	new incorporation
mA	100	1.38	0.73	X 93.7	68	1.02
mG	100	0.98	1.02	X 93.7	95	0.90
biA	100	0.97	1.03	X 93.7	96	1.10
nC	100	0.67	1.49	X 93.7	140	0.97#

* normalized to give 400 µl total volume

5

Example 3

Noncompetitive Homogeneous Coupling Method for the
Preparation of Oligonucleotides with "Fixed" positions.

16 μM of dT-CPG solid support was divided into four

5   equal 4 μM aliquots. Each aliquot was reacted with 17 equiv.
of one of 2'-O-methyl adenosine (mA), 2'-O-methyl guanosine
(mG), 2'-O-butylimidazolyl adenosine (biA), or 2'-O-nonyl
cytidine (nC) amidites until completion using standard solid
state synthesis coupling cycles. The extent of reaction was

10 determined to be at least 90% completed, as described
previously in Example 1B. The aliquots were mixed thoroughly
and again divided into four equal aliquots. Each aliquot was
reacted with 17 equiv. of one of the 2'-O-methyl adenosine
(mA), 2'-O-met '1 guanosine (mG), 2'-O-butylimidazolyl

15 adenosine (biA), or 2'-O-nonyl cytidine (nC) amidites, as
above, until completion. The cycle was repeated three times
for a total of three random positions.

The 16 μM of CPG solid support was divided into four
equal 4 μM aliquots. Each aliquot was reacted with 17 equiv.

20 of one of 2'-O-methyl adenosine (mA), 2'-O-methyl guanosine
(mG), 2'-O-butylimidazolyl adenosine (biA), or 2'-O-nonyl
cytidine (nC) amidite until completion. The aliquots were not
mixed, but kept separate to obtain a unique residue in the
fifth position of each of the four pools.

25 Thereafter each of the four aliquots were divided into
four subsets of 1 μM. One subset from each aliquot was reacted
with one of 17 equiv. of one of 2'-O-methyl adenosine (mA), 2'-
O-methyl guanosine (mG), 2'-O-butylimidazolyl adenosine (biA),
or 2'-O-nonyl cytidine (nC) amidites until completion using

30 standard solid state synthesis coupling cycles. The subsets
from each aliquot were mixed together, resulting in four·
aliquots. Thereafter the four aliquots were apportioned into
sub-sets and each subset of each aliquot is again reacted with
one of 2'-O-methyl adenosine (mA), 2'-O-methyl guanosine (mG),

35 2'-O-butylimidazolyl adenosine (biA), and 2'-O-nonyl cytidine
(nC) amidites until completion using standard solid state

- 20 -

synthesis coupling cycles. This procedure was repeated three times for a total of three more random positions. There was a final reaction with dT amidite to give all of the four pools a 5'-terminal dT. The resultant four randomer oligonucleotide
5 pools each have a 3'-terminal dT, followed by three random positions, a fixed monomer (either mA, mG, biA, or nC) in the fifth position, three more random positions, and finally a 5'-terminal dT. This is represented by the sequence notation 5'-TNNNXNNNT,in which N are random positions and X is a unique
10 fixed position.

       Example 5
            Post Synthesis Analysis
            A typical digestion/HPLC analysis was performed as follows. For each digestion 1 μL each of Nuclease P1 (BRL, 33
15 units/μL), bacterial alkaline phosphatase (BAP) (BRL, 150 units/μL), and snake venom phosphodiesterase (SVP) (Pharmacia, 0.1 units/μL) was added to 2 μL of 10X buffer (140 mM MgCl$_2$, 720 mM NaCl, 500 mM tris-HCl pH 8.5) and 13 μL water. 2 μL of oligonucleotide (1 mM in strands; 0.2 A$_{260}$ units) was added for
20 a total volume of 20 μL, and the mixture was incubated at 37°C overnight.
            After incubation, 2.5 volumes (60 μL) of methanol was added to each digestion (to prevent selective binding of lipophilic nucleosides during ultrafiltration) and each was
25 mixed well. The supernatant was passed through a centrifugal 10,000 NMW cut-off ultrafilter (Millipore, #UFC3 TGC 00) to remove enzymes, dried by evaporation, dissolved in HPLC starting mobil-phase, and analyzed by HPLC (0-90% B in A over 40 minutes) at 260 nm.
30   For the oligonucleotide TNNNXNNNT, in which X = 2'-O-butylimidazolyladenosine (biA), and each N is one of 2'-O-methylguanosine (mG), 2'-O-methyladenosine (mA), 2'-O-butylimidazolyladenosine (biA), or 2'-O-nonylcytidine (nC), the expected and experimental ratios are summarized in Table II.

- 21 -

Table II

monomer	expected relative ratio	experimental relative ratio	normalized experimental relative ratio exper./expec.
dT	2.00	2.16	1.08
mG	1.50	1.67	1.12
mA	2.50	2.67	1.07
biA	1.50	1.29	0.86
nC	1.50	1.21	0.81

This result shows that all four residues were well represented in nearly equal proportions in the oligonucleotide pool.

Example 6

PLA$_2$ Assay

Phospholipase A$_2$ (PLA$_2$) enzymes are responsible for the hydrolysis of the *sn-2* linkage of membrane phospholipids. PLA$_2$-catalyzed reaction is the rate-limiting step in the release of a number of pro-inflammatory mediators, and type II PLA$_2$ is implicated in the pathogenesis of several human inflammatory diseases. Library subsets were screened for inhibition of the activity of type II PLA$_2$ and a unique inhibitor was identified.

The oligomer libraries were screened for inhibition of PLA$_2$ in an assay using *E. coli* cells labeled with ^{3}H-oleic acid as the substrate. Franson *et al.*, *J. Lipid Res.* **1974**, *15*, 380; and Davidson *et al.*, *J. Biol. Chem.* **1987**, *262*, 1698. Type II PLA$_2$ (originally isolated from synovial fluid), expressed in a baculovirus system and partially purified, serves as a source of the enzyme. A series of dilutions (in water) of each of the oligomeric pools was made: 10 μL of each oligomer was incubated for 5 minutes at room temperature with a mixture of 10 μL of PLA$_2$, 20 μL 5 x PLA$_2$, buffer (500 mM Tris, pH 7.0-7.5, 5 mM CaCl2) and 50 μL water. Each of the oligomer samples was run

- 22 -

in duplicate. At this point, 10 μL of ^{3}H-labeled *E. coli* cells
was added. This mixture was incubated at 37°C for 15 minutes.
The enzymatic reaction was halted with the addition of 50 μL of
2 M HCl and 50 μL of fatty acid-free BSA (20 mg/mL PBS),
5 vortexed for 5 seconds and centrifuged at high speed for 5
minutes. A 165 μL portion of each supernatant was then put
into a scintillation vial containing 6 mL of scintillant
(Scintiverse) and cpms were measured in a Beckman Liquid
Scintillation Counter. As a control, a reaction without
10 oligomer was run alongside the other reactions as well as a
baseline reaction containing neither oligomer nor PLA$_2$ enzyme.
Cpms were corrected for by subtracting the baseline from each
reaction data point. The results are shown in Tables III, IV
and V.

15   **TABLE III**

Round	Sequence*	Most Active X=	IC$_{50}$ (μM)
1	G$_4$XNNNG$_4$	egCB	25
2	G$_4$(egCB)XNNG$_4$	egCB	12

*N represents an equimolar mixture of dA, dG, dC, dT, egCB and
20 egIM.

The first round identified G$_4$(egCB)NNNG$_4$ as the best
oligomer with an IC$_{50}$ of 25 μM. The next position was also
determined to be egCB, with a two-fold improvement in activity
and an IC$_{50}$ of 12 μM. As a result, at the end of two rounds of
25 selection, G$_4$(egCB)$_2$NNG$_4$ was identified to the best oligomer in
the PLA$_2$ assay.

                           TABLE IV

Round	Sequence*	Most Active X=	IC$_{50}$ (μM)
1	XNNNdT	nC	30
30 2	(nC)XNNdT	nC	20
3	(nC)(nC)XNdT	dG	10
4	(nC)(nC)dGXdT	dT	2

*N represents an equimolar mixture of BT1, BT2, mA, mU, pG, nC, dG, dT, egNH, egCB, egIM and mmU.

The first two rounds were useful for the determination of the first two monomer units, i.e. nC, of the oligomer. The next two positions were determined to be dG and dT, in that order, and the unique oligomer with the greatest activity was identified to be (nC)(nC)(dG)(dT)(dT) with an IC_{50} of 2 μM.

TABLE V

Round	Sequence*	Most Active X=	IC_{50} (μM)
1	XNNNNdT	egOC	40
2	(egOC)XNNNdT	egOC	5
3	(egOC)(egOC)XNNdT	egOC	1.5

*N represents an equimolar mixture of egIM, egOC, egNH, hpPH, hpSU and hpNY.

The first round selected (egOC)NNNNdT as the most active subset with an IC_{50} of 40 μM. The next round led to the determination of the monomer unit in the second position of the oligomer, i.e. egOC, with an eight-fold improvement in activity and an IC_{50} of 5 μM. The third round of synthesis and selection led to the identification of (egOC)(egOC)(egOC)NNdT as the most active subset with a still further improved IC_{50} of 1.5 μM. Further rounds can be used to identify a unique oligomer with the greatest activity in the PLA_2 assay.

Example 7

Leukotriene B₄ assay

Leukotriene B_4 (LTB_4) has been implicated in a variety of human inflammatory diseases, and its pharmacological effects are mediated via its interaction with specific surface cell receptors. Library subsets were screened for competitive inhibition of radiolabeled LTB_4 binding to a receptor preparation.

- 24 -

A Nenquest™ Drug Discovery System Kit (NEN Research Products, Boston, MA) was used to select an inhibitor of the interaction of Leukotriene B₄ (LTB₄) with receptors on a preparation of guinea pig spleen membrane. [³H] Leukotriene B₄

5 reagent was prepared by adding 5 mL of ligand diluent (phosphate buffer containing NaCl, MgCl₂, EDTA and Bacitracin, pH 7.2) to 0.25 mL of the radioligand. The receptor preparation was made by thawing the concentrate, adding 35 mL of ligand diluent and swirling gently in order to resuspend the

10 receptor homogenously. Reagents were kept on ice during the course of the experiment, and the remaining portions were stored at -20°C.

The library subsets were diluted to 5 μM, 50 μM and 500 μM in phosphate buffer (1x PBS, 0.1% azide and 0.1% BSA, pH

15 7.2), yielding final test concentrations of 0.5 μM, 5 μM and 50 μM, respectively. Samples were assayed in duplicate. [³H] LTB₄ (25 μL) was added to 25 μL of either appropriately diluted standard (unlabeled LTB₄) or library subset. The receptor suspension (0.2 mL) was added to each tube. Samples were

20 incubated at 4°C for 2 hours. Controls included [³H] LTB₄ without receptor suspension (total count vials), and sample of ligand and receptor without library molecules (standard).

After the incubation period, the samples were filtered through GF/B paper that had been previously rinsed with cold

25 saline. The contents of each tube were aspirated onto the filter paper to remove unbound ligand from the membrane preparation, and the tubes washed (2 x 4 mL) with cold saline. The filter paper was removed from the filtration unit and the filter disks were placed in appropriate vials for scintillation

30 counting. Fluor was added, and the vials shaken and allowed to stand at room temperature for 2 to 3 hours prior to counting. The counts/minute (cpm) obtained for each sample were subtracted from those obtained from the total count vials to determine the net cpm for each sample. The degree of

35 inhibition of binding for each library subset was determined relative to the standard (sample of ligand and receptor without library molecules). The results are shown in Tables VI, VII

- 25 -

and VIII.

TABLE VI

Round	Sequence*	Most Active X=	IC_{50} (μM)
1	XNNNNNdT	egCB	11
2	(egCB)XNNNNdT	egCB	2
3	(egCB)(egCB)XNNNdT	egCB	0.7

*N represents an equimolar mixture of egA, egG, egC, egT, egCB and egIM.

In the initial round of screening, the subset with egCB in the first position, *i.e.* (egCB)NNNNNdT, showed greatest activity. In the second round, subset (egCB)(egCB)NNNNdT was most active, and the activity increased from an IC_{50} of 11 μM in round 1 to 2 μM in round 2, an approximately 6-fold increase in activity. Assay of round 3 subsets resulted in the identification of (egCB)(egCB)(egCB)NNNdT with improved activity and an IC_{50} of 0.7 μM. Synthesizing and assaying further rounds of subsets leads to the identification of a unique oligomer demonstrating the best activity in the LTB_4 assay.

TABLE VII

Round	Sequence*	Most Active X=	IC_{50} (μM)
1	XNNNdT	egCB	40
2	(egCB)XNNdT	egCB	6
3	(egCB)(egCB)XNdT	BT1	1.7
4	(egCB)(egCB)(BT1)XdT	egCB	0.7

*N represents an equimolar mixture of BT1, BT2, mA, mU, pG, nC, dG, dT, mmU, egNH, egCB and egIM.

In the initial round of screening, the subset with egCB in the first position, *i.e.* (egCB)NNNdT, showed greatest activty. In the second round, subset (egCB)(egCB)(NNdT was most active, and the activity increased from an IC_{50} of 40 μM

- 26 -

in round 1 to 6 μM in round 2, an approximately seven-fold improvement in activity. Assay of subsets from rounds 3 and 4 resulted in the identification of the most active oligomer, i.e. (egCB)(egCB)(BT1)(egCB)dT, with the lowest IC_{50} of 0.7 μM.

TABLE VIII

Round	Sequence*	Most Active X=	IC_{50} (μM)
1	XNNNNdT	egOC	15
2	(egOC)XNNNdT	egOC	7
3	(egOC)(egOC)XNNdT	egIM	2

*N represents an equimolar mixture of egCB, egIM, egNH, hpPH, hpSU and hpNY.

The first two rounds of synthesis and selection were useful in the determination of the first two monomer units of the oligomer, i.e. (egOC)(egOC)NNNdT, with an IC50 of 7 μM. The next round led to the selection of an oligomer with an improved IC50 of 2 μM. Further rounds can be performed for the identification of a unique oligomer with the best activity.

Example 8

Assay for Detection of Inhibition of Human Immunodeficiency Virus

An *in vitro* HIV infection assay was used to select inhibitors of HIV replication from combinatorial libraries. Buckheit *et al.*, *Antiviral Res.* **1993**, *21*, 247. Human T-lymphoblastoid CEM cell line was maintained in an exponential growth phase in RPMI 1640 with 10% fetal calf serum, glutamine, and antibiotics. On the day of the assay, the cells were washed and counted by trypan blue exclusion. These cells (CEM-IIIB) were seeded in each well of a 96-well microtiter plate at 5 X 10^3 cells per well. Following the addition of cells to each well, the library subsets were added at the indicated concentrations and serial half log dilutions. Infectious HIV-1_{IIIB} was immediately added to each well at a multiplicity of

- 27 -

infection determined to give complete cell killing at 6 days post-infection. Following 6 days of incubation at 37°C, an aliquot of supernatant was removed from each well prior to the addition of the tetrazolium dye XTT to each well. The XTT was
5 metabolized to a formazan blue product by viable cells which was quantitatively measure spectrophotometrically with a Molecular Devices Vmax Plate Reader. The XTT assay measures protection from the HIV-induced cell killing as a result of the addition of test compounds. The supernatant aliquot was
10 utilized to confirm the activities determined in the XTT assay. Reverse transcriptase assays and p24 ELISA were performed to measure the amount of HIV released from the infected cells. Protection from killing results in an increased optical density in the XTT assay and reduced levels of viral reverse
15 transcriptase and p24 core protein. The results are shown in Table IX.

TABLE IX

Round	Sequence*	Most Active X=	IC_{50} (μM)
1	G_4XNNNG_4	egCB	4
20 2	G_4(egCB)XNNG$_4$	egCB	2

*N represents an equimolar mixture of dA, dT, dG, dC, egCB and egIM.

Two rounds of synthesis and selection led to the determination of the subset G_4(egCB)(egCB)NNG$_4$ as the best
25 subset with an IC_{50} of 2 μM. Additional rounds can performed for the identification of a unique oligomer with further increase in activity.

- 28 -

What is claimed is:

      1.   A method of preparing a random phosphate linked oligomer library comprising:

      (a) selecting a group of phosphorous bearing monomers;

5   (b) testing said group of monomers for chemical suitability with respect to at least one predetermined parameter;

      (c) selecting from said group of phosphorous bearing monomers a sub-group of monomers that are chemically suitable

10 with respect to said predetermined parameter;

      (d) reacting each of the members of said sub-group of monomer to a standard reactive site located on a solid support;

      (e) analyzing the relative coupling efficiency of each of said members of said sub-group of monomer unit with said

15 standard reactive site;

      (f) preparing a mixture of said members of said sub-group of phosphorous bearing monomer units in accordance with coupling efficiencies determined in step (e);

      (g) reacting via phosphate coupling said adjusted

20 mixture of phosphorous bearing monomer units of said sub-group to a solid support or growing oligomer chain; and

      (h) repeating step (g) in order to prepare a random oligomer library comprising oligomers of a desired length.

      2.   The method of claim 1 further including:

25   selecting an internal reference standard; and

      adding said internal reference standard to said solid support having said standard reactive site prior to reacting said members of said sub-group to said standard reactive site.

30   3.   An oligomer prepared by the method of claim 1.

      4.   The method of claim 1 wherein said chemically suitable predetermined parameters are selected from the group consisting of degree of incorporation, efficiency of incorporation, predominance of a desired product, compatibility

35 of synthesis conditions, deprotection conditions, standard

- 29 -

solubilizing reagent requirements, standard coupling reagent
requirements, non-excessive reagent usage, non-excessive
reaction time, non-excessive deprotection time, and non-
compatible acid or base conditions.

5   5.   The method of claim 4 wherein said chemically
suitable predetermined parameters are selected from the group
consisting of degree of incorporation, efficiency of
incorporation, predominance of a desired product, compatibility
of synthesis conditions, and compatibility of deprotection
10 conditions.

         6.   The method of claim 1 further including selecting
said solid support in said step (g) to have a number of
reactive sites that is at least two orders of magnitude greater
than the number of the individual nucleotides in any of said
15 oligomers that will make up said oligomer library.

         7.   The method of claim 1 wherein the relative
coupling efficiency of said members of said sub-group is
analyzed by determining a relative incorporation with respect
to a standard, taking the inverse of said relative
20 incorporation, and normalizing said inverse of said relative
incorporation with respect to the totality of said members.

         8.   The method of claim 1 including repeating at
least one further iteration of steps (d) and (e) using the
determined coupling efficiency of a previous step (e) to
25 calculate a new coupling efficiency for the further iteration.

         9.   The method of claim 1 further including
incorporating at least one fixed position in said growing
oligomer by:
30   reacting via phosphate coupling a single one of said
members of said sub-group to said solid support or growing
oligomer chain.

- 30 -

10. The method of claim 1 wherein the phosphate coupling is selected from the group consisting of amidite, triester, H-phosphonate, halide and solution phase phosphate coupling.

5   11. A method of preparing a random phosphate linked oligomer library comprising:

(a) selecting a group of phosphorous bearing monomers;

(b) testing said group of monomers for chemical suitability with respect to at least one predetermined

10 parameter;

(c) selecting from said group of phosphorous bearing monomers a sub-group of monomers that are chemically suitable with respect to said predetermined parameter;

(d) reacting each of the members of said sub-group of

15 monomer to a standard reactive site located on a solid support;

(e) analyzing the relative coupling efficiency of each of said members of said sub-group of monomer unit with said standard reactive site;

(f) selecting a quantity of solid support;

20   (g) dividing said solid support into aliquots, the number of said aliquots equal to the number of said members of said sub-group;

(h) reacting via a phosphate coupling each of said members of said sub-group of phosphorous bearing monomer units

25 in accordance with coupling efficiencies determined in step (e) with one of said aliquots of said solid support to attach said members to said solid support or to attach said members to a growing oligomer chain located on said solid support;

(i) mixing each of said aliquots of said solid support

30 together; and

(j) repeating steps (g), (h) and (i) in order to prepare a random oligomer library comprising oligomers of a desired length.

12. The method of claim 11 further including:

- 31 -

selecting an internal reference standard; and

adding said internal reference standard to said solid support having said standard reactive site prior to reacting said members of said sub-group to said standard reactive site.

5

13.   An oligomer prepared by the method of claim 11.

14.   The method of claim 11 wherein said chemically suitable predetermined parameters include degree of incorporation, efficiency of incorporation, predominance of a

10   desired product, compatibility of synthesis conditions, deprotection conditions, standard solubilizing reagent requirements, standard coupling reagent requirements, non-excessive reagent usage, non-excessive reaction time, non-excessive deprotection time, or non-compatible acid or base

15   conditions.

15.   The method of claim 14 wherein said chemically suitable predetermined parameters include degree of incorporation, efficiency of incorporation, predominance of a desired product, compatibility of synthesis conditions, or

20   deprotection conditions.

16.   The method of claim 11 further including selecting said solid support in said step (f) to have a number of reactive sites that is at least two orders of magnitude greater than the number of the individual nucleotides in any of

25   said oligomers that make up said oligomer library.

17.   The method of claim 11 wherein the relative coupling efficiency of said members of said sub-group is analyzed by determining a relative incorporation with respect to a standard, taking the inverse of said relative

30   incorporation, and normalizing said inverse of said relative incorporation with respect to the totality of said members.

- 32 -

18. The method of claim 11 including repeating at least one further iteration of steps (d) and (e) using the determined coupling efficiency of the prior step (e) to calculate a new coupling efficiency for the further iteration.

19. The method of claim 11 further including incorporating at least one fixed position in said growing oligomer by:

reacting a single one of said members of said sub-group to said solid support or growing oligomer chain.

20. The method of claim 11 further including incorporating at least one null position in a portion of said growing oligomer by:

dividing said solid support into aliquots, the number of said aliquots equal to one more than the number of said members of said sub-group; and

reacting via a phosphate coupling each of said members of said sub-group of phosphorous bearing monomer units in accordance with coupling efficiencies determined in step (e) with one of said aliquots of said solid support such that one of said aliquots is left unreacted.

21. The method of claim 11 further including incorporating at least one position in said growing oligomer that excludes at least one of said monomers of said sub-group by:

dividing said solid support into aliquots, the number of said aliquots equal to less than the number of said members of said sub-group; and

reacting via a phosphate coupling less than all of said members of said sub-group of phosphorous bearing monomer. units in accordance with coupling efficiencies determined in step (e) with one of said aliquots of said solid support.

22. The method of claim 11 wherein the phosphate coupling is selected from the group consisting of amidite,

- 33 -

triester, H-phosphonate, halide and solution phase phosphate coupling.

23.   A method of preparing a random phosphate linked oligomer library comprising:

5   (a) selecting a group of phosphorous bearing monomers to be tested;

(b) testing the phosphorous bearing monomers for chemical suitability;

(c) selecting from the group of phosphorous bearing 10 monomers, monomers which are chemically suitable;

(d) individually reacting to completion each of the chemically compatible phosphorous bearing monomers with a solid support or growing oligomer chain with phosphate couplings;

(e) mixing all of the solid supports to form a 15 mixture;

(f) dividing the mixture in portions; and

(g) repeating steps (d), (e) and (f) in order to prepare a random oligomer library comprising oligomers of desired length.

20   24.   The method of claim 23 wherein the phosphate coupling is selected from the group consisting of amidite, triester, H-phosphonate, halide and solution phase phosphate coupling.

25.   An oligomer prepared by the method of claim 23.

25   26.   A method of analyzing monomers for suitability of use in preparing oligomer comprising:

(a)   select first monomer-solid support couple, said first monomer-solid support couple selected such that said monomer is a monomer that is reactive for oligomeric synthesis 30 on said solid support;

(b) select a second monomer-solid support couple, said second monomer-solid support coupled selected such that said second monomer is a monomer that is non-reactive for oligomeric

- 34 -

synthesis on said solid support;

     (c)   mix said first and said second monomer-solid support couples in a known gross ratio;

     (d)   determine the exact ratio of said first and 5 second monomers in said mixture;

     (e)   select a further monomer;

     (f)   react said further monomer with said mixture to couple said further monomer and said first monomer;

     (g)   determine the relative amounts of the products 10 resulting from said reaction of said further monomer with said mixture; and

     (h)   calculate from said relative amounts of said products and said exact ratio of said first and second monomers in said mixture at least one of i) one coupling efficiency of 15 said further monomer, ii) extinction coefficient of the coupling product of said further monomer with said first monomer and iii) presence of products other than the expected coupling product of said further monomer.

     27.   The method of claim 26 wherein said determination 20 of said exact ratio of said first and second monomer is effected using the extinction coefficients of said monomers.

     28.   The method of claim 26 wherein said determination of said relative amounts of the products resulting from said reaction of said further monomer with said mixture is effected 25 by analysis of the peak area of a HPLC chromatogram of said products.

     29.   The method of claim 28 wherein said products are liberated from said solid support prior to said HPLC analysis.

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12Q 1/68; C07H 15/12, 17/00
US CL : 435/6; 536/23.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6; 536/23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO, A, 92/00091 (LAM ET AL) 09 January 1992, see especially "Summary of the Invention" beginning page 6 and page 10, beginning line 8.	1-29

☐ Further documents are listed in the continuation of Box C.　　☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	
"E" earlier document published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
04 APRIL 1995	18 APR 1995

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer　Deborah Fruse for MINDY B. FLEISHER
Facsimile No.　(703) 305-3230	Telephone No.　(703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)★